A phase II, multicenter, open-label, dose-finding study evaluating THIO sequenced with cemiplimab in patients with advanced NSCLC

被引：0
|
作者：
Ciuleanu, T-E. [1 ]
Joshi, R. [2 ]
Gryaznov, S. [3 ]
Vitoc, V. [3 ]
Obrocea, M. [3 ]
机构：
[1] IOCN Oncol Inst Prof Dr Ion Chiricuta, Med Oncol, Cluj Napoca, Romania
[2] Canc Res SA, Med Oncol, Adelaide, SA, Australia
[3] MAIA Biotechnol Inc, Clin Dev, Chicago, IL USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1316
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1193TiP
引用
收藏
页码：S1094 / S1094
页数：1
相关论文
共 50 条
  • [41] A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
    Tolcher, Anthony W.
    Appleman, Leonard J.
    Shapiro, Geoffrey I.
    Mita, Alain C.
    Cihon, Frank
    Mazzu, Arthur
    Sundaresan, Pavur R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 751 - 764
  • [42] Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
    Zucali, Paolo Andrea
    Lin, Chia-Chi
    Carthon, Bradley C.
    Bauer, Todd M.
    Tucci, Marcello
    Italiano, Antoine
    Iacovelli, Roberto
    Su, Wu-Chou
    Massard, Christophe
    Saleh, Mansoor
    Daniele, Gennaro
    Greystoke, Alastair
    Gutierrez, Martin
    Pant, Shubham
    Shen, Ying-Chun
    Perrino, Matteo
    Meng, Robin
    Abbadessa, Giovanni
    Lee, Helen
    Dong, Yingwen
    Chiron, Marielle
    Wang, Rui
    Loumagne, Laure
    Lepine, Lucie
    de Bono, Johann
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [43] A phase II, randomized, open-label, dose-finding study of TAS-108, a novel steroidal antiestrogen, administered orally in postmenopausal women with advanced or metastatic breast cancer.
    Iwata, H.
    Inaji, H.
    Nakayama, T.
    Yamamoto, N.
    Noguchi, S.
    Ikeda, T.
    CANCER RESEARCH, 2009, 69 (02) : 195S - 196S
  • [44] UNBLOCK: an open-label, dose-finding, pharmacokinetic and safety study of bivalirudin in children with deep vein thrombosis
    O'Brien, S. H.
    Yee, D. L.
    Lira, J.
    Goldenberg, N. A.
    Young, G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (09) : 1615 - 1622
  • [45] Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease
    Besarab, Anatole
    Salifu, Moro O.
    Lunde, N. Martin
    Bansal, Vinod
    Fishbane, Steven
    Dougherty, Frank C.
    Beyer, Ulrich
    CLINICAL THERAPEUTICS, 2007, 29 (04) : 626 - 639
  • [46] Open-label dose-finding trial of buprenorphine implants (Probuphine)® for treatment of heroin dependence
    White, Jason
    Bell, James
    Saunders, John B.
    Williamson, Paul
    Makowska, Maria
    Farquharson, Aaron
    Beebe, Katherine L.
    DRUG AND ALCOHOL DEPENDENCE, 2009, 103 (1-2) : 37 - 43
  • [47] Evaluating dose regimens of apomorphine, an open-label study
    A Kongkanand
    J Opanuraks
    K Tantiwongse
    N Choeypunt
    A Tantiwong
    T Amornvejsukit
    International Journal of Impotence Research, 2003, 15 : S10 - S12
  • [48] HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)
    Durrant, Simon
    Koren-Michowitz, Maya
    Lavie, David
    Martinez-Lopez, Joaquin
    Vannucchi, Alessandro M.
    Passamonti, Francesco
    Stalbovskaya, Viktoriya
    Atienza, Edric
    Iommazzo, Dana
    Gopalakrishna, Prashanth
    Gisslinger, Heinz
    BLOOD, 2014, 124 (21)
  • [49] Evaluating dose regimens of apomorphine, an open-label study
    Kongkanand, A
    Opanuraks, J
    Tantiwongse, K
    Choeypunt, N
    Tantiwong, A
    Amornvejsukit, T
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2003, 15 (Suppl 2) : S10 - S12
  • [50] Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
    Simonelli, M.
    Garralda, E.
    Eskens, F.
    Gil-Martin, M.
    Yen, C-J
    Obermannova, R.
    Chao, Y.
    Lonardi, S.
    Melichar, B.
    Moreno, V
    Yu, M-L
    Bongiovanni, A.
    Calvo, E.
    Rottey, S.
    Machiels, J-P
    Gonzalez-Martin, A.
    Paz-Ares, L.
    Chang, C-L
    Mason, W.
    Lin, C-C
    Reardon, D. A.
    Vieito, M.
    Santoro, A.
    Meng, R.
    Abbadessa, G.
    Menas, F.
    Lee, H.
    Liu, Q.
    Combeau, C.
    Ternes, N.
    Ziti-Ljajic, S.
    Massard, C.
    ESMO OPEN, 2022, 7 (05)
12345